DH Stock Overview
Provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Definitive Healthcare Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.18 |
| 52 Week High | US$10.62 |
| 52 Week Low | US$3.19 |
| Beta | 1.4 |
| 1 Month Change | -4.35% |
| 3 Month Change | -3.24% |
| 1 Year Change | -57.30% |
| 3 Year Change | -85.26% |
| 5 Year Change | n/a |
| Change since IPO | -90.34% |
Recent News & Updates
Recent updates
Definitive Healthcare: Poor Near-Term Outlook, But New CEO May Change Things
Aug 19More Unpleasant Surprises Could Be In Store For Definitive Healthcare Corp.'s (NASDAQ:DH) Shares After Tumbling 28%
Aug 01
Definitive Healthcare: Weak Near-Term Growth To Put Valuation In Rangebound
Jun 25Risks Still Elevated At These Prices As Definitive Healthcare Corp. (NASDAQ:DH) Shares Dive 26%
May 30Pinning Down Definitive Healthcare Corp.'s (NASDAQ:DH) P/S Is Difficult Right Now
Apr 14Definitive Healthcare: Reiterate Buy Rating As I Expect Growth To Recover In FY25
Mar 19Is Definitive Healthcare (NASDAQ:DH) Using Debt In A Risky Way?
Feb 16An Intrinsic Calculation For Definitive Healthcare Corp. (NASDAQ:DH) Suggests It's 42% Undervalued
Dec 29Definitive Healthcare Corp. (NASDAQ:DH) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected
Nov 24Estimating The Fair Value Of Definitive Healthcare Corp. (NASDAQ:DH)
Jun 02Definitive Healthcare Corp. (NASDAQ:DH) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 06A Look At The Fair Value Of Definitive Healthcare Corp. (NASDAQ:DH)
Dec 08Definitive Healthcare Grows Headcount Despite Gathering Recession Clouds
Aug 31Definitive Healthcare Corp.'s (NASDAQ:DH) Intrinsic Value Is Potentially 27% Above Its Share Price
Jul 17Definitive Healthcare: No Involvement Yet Here
Jun 05Shareholder Returns
| DH | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -6.9% | -0.002% | -2.4% |
| 1Y | -57.3% | 2.2% | 23.4% |
Return vs Industry: DH underperformed the US Healthcare Services industry which returned 1.9% over the past year.
Return vs Market: DH underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| DH volatility | |
|---|---|
| DH Average Weekly Movement | 5.1% |
| Healthcare Services Industry Average Movement | 9.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 950 | Kevin Coop | www.definitivehc.com |
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company’s platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management.
Definitive Healthcare Corp. Fundamentals Summary
| DH fundamental statistics | |
|---|---|
| Market cap | US$647.55m |
| Earnings (TTM) | -US$364.28m |
| Revenue (TTM) | US$255.85m |
1.9x
P/S Ratio-1.3x
P/E RatioIs DH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DH income statement (TTM) | |
|---|---|
| Revenue | US$255.85m |
| Cost of Revenue | US$39.16m |
| Gross Profit | US$216.68m |
| Other Expenses | US$580.96m |
| Earnings | -US$364.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.15 |
| Gross Margin | 84.69% |
| Net Profit Margin | -142.38% |
| Debt/Equity Ratio | 35.4% |
How did DH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Definitive Healthcare Corp. is covered by 19 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Vruwink | Baird |
| Saket Kalia | Barclays |
| Allen Lutz | BofA Global Research |